Healthcare / Drug Manufacturers - Specialty & GenericNasdaqCM
$1.49
-0.07 (-4.81%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-7.4M · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$5M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-60.8%
↓Gross Margin
34.5%
↓Debt/Equity
0.06
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-157.1%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.9M · net income $-8.2M · FCF $-7.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $4.9M | $4.9M | $4.6M | $4.1M | $1.1M | $1.9M | — |
| Net Income | $-8.2M | $-8.2M | $-7.7M | $-7.9M | $-18.6M | $-10.2M | $-8.9M |
| EBITDA | $-7.3M | $-7.3M | $-7.1M | $-7.8M | $-13.3M | $-10.1M | — |
| EPS | -8.36 | -8.36 | -20.20 | -65.00 | -663.40 | -759.20 | — |
| Gross Margin | 34.5% | 34.5% | 23.9% | 33.9% | 49.9% | — | — |
| Operating Margin | -160.2% | -160.2% | -176.9% | -202.6% | -1266.0% | -535.9% | — |
| Net Margin | -165.1% | -165.1% | -166.9% | -192.2% | -1707.3% | -535.9% | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.06 | 0.06 | 0.10 | 0.03 | 0.09 | — | — |
| Current Ratio | 3.12 | 3.12 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-7.8M | $-7.8M | $-7.0M | $-7.4M | $-15.6M | $-9.8M | $-7.4M |
| Returns | |||||||
| ROE | -60.8% | -60.8% | -83.4% | -65.7% | -204.9% | -138.3% | -152.1% |
| Valuation | |||||||
| P/B | 0.11 | 0.11 | 0.22 | 0.20 | 0.73 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 7.5% | 7.5% | 11.2% | 279.6% | — | — | — |
| EPS Growth | 58.6% | 58.6% | 68.9% | 90.2% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-56.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-20.20 → -8.36
Residual
-56.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.